

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) An inhibitor of histone deacetylase represented by formula (1):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

X is selected from the group consisting of C=O, C=CH<sub>2</sub>, CH(OH), CH(OR<sup>1</sup>), C=N(OH), and C=N(OR<sup>1</sup>), where R<sup>1</sup> is alkyl, aryl, aralkyl, or acyl;

Y<sup>1</sup> is a C<sub>3</sub>-C<sub>7</sub> alkylene, wherein said alkylene may be optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting X and W may be replaced with O, NR<sup>3</sup>, or S(O)<sub>n</sub>, where R<sup>3</sup> is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or caramoyl, and n is 0, 1, or 2, provided that the atoms in Y<sup>1</sup> that are attached to X and W are carbon atoms, and further provided that Y<sup>1</sup> is not an ester or amide linkage in the linear chain connecting X and W; and

W is selected from the group consisting of -C(O)-CH<sub>2</sub>-SR<sup>2</sup>, -C(O)-NH-OM, -NH-C(O)-NH-Z, and -C(O)-NH-Z, where

R<sup>2</sup> is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen or a pharmaceutically acceptable cation;


Z is selected from the group consisting of aniliny, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinylmethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy;

provided that X is C=CH<sub>2</sub>, CH(OR), C=N(OH), or C=N(OR<sup>1</sup>) when W is -C(O)-NH-OM and Cy is unsubstituted phenyl, dimethylaminophenyl, or methoxyphenyl; and further provided that when W is -C(O)-CH<sub>2</sub>-SR<sup>2</sup>, the carbon atom in Y<sup>1</sup> that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl;

~~or a pharmaceutically acceptable salt thereof.~~

2. (Original) The inhibitor of claim 1, wherein Cy is C<sub>6</sub>-C<sub>10</sub> aryl or is a radical of a heterocyclic moiety selected from the group consisting of thiophene, benzothiophene, furan, benzofuran, pyridine, quinoline, indole, isoquinoline, thiazole, morpholine, piperidine, and piperazine, any of which groups may be optionally substituted.
3. (Original) The inhibitor of claim 2, wherein the aryl or heterocyclic moiety is substituted by one or two substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl, heteroaryl, heterocyclyl, (C<sub>6</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>6</sub>-C<sub>10</sub> aryloxy, heteroaryloxy, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, C<sub>6</sub>-C<sub>10</sub> aryloxycarbonyl, heteroaryloxycarbonyl, carboxy, and amino.
4. (Previously Amended) The inhibitor of claim 1, wherein Cy has the formula -Cy<sup>1</sup>-CY<sup>2</sup> or Cy<sup>1</sup>-G-Cy<sup>2</sup>, wherein Cy<sup>1</sup> and Cy<sup>2</sup> are independently C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>6</sub>-C<sub>10</sub> aryl, or a radical of a heterocyclic moiety, which groups optionally may be substituted, and G is O, NR<sup>3</sup> or S(O)<sub>n</sub>, where R<sup>3</sup> is hydrogen alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2.
5. (Cancelled)

6. (Original) The inhibitor of claim 1, where X is selected from the group consisting of  $\text{CH}(\text{OR}^1)$ ,  $\text{C}=\text{N}(\text{OH})$ , and  $\text{C}=\text{N}(\text{OR}^1)$ , where  $\text{R}^1$  is  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_6$ - $\text{C}_{10}$  aryl, or  $(\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl}$ .
7. (Previously amended) The inhibitor of claim 1, wherein one to three carbon atoms of the alkylene are independently substituted with halo, oxo, oximino, nitro, haloalkyl, alkyl, aralkyl, alkoxy, aryloxy, alkoxy carbonyl, carboxy, hydroxyalkyl, acyl, acyloxy, or cyano.
8. (Currently amended) The inhibitor of claim 1, wherein  $\text{Y}^1$  ~~comprises~~ is an all carbon linear chain connecting X and W.
9. (Currently amended) The inhibitor of claim 8, wherein the linear chain connecting X and W ~~comprises~~ is a dienyl moiety, wherein the dienyl moiety is attached to W.
10. (Previously Amended) The inhibitor of claim 9, wherein  $\text{Y}^1$  is selected from the group consisting of



11. (Original) The inhibitor of claim 8, wherein  $\text{Y}^1$  is  $-(\text{CH}_2)_m$ , where m is 5, 6, or 7.
12. (Original) The inhibitor of claim 1, wherein one carbon atom in the linear chain connecting X and W is replaced with O,  $\text{NR}^3$ , or  $\text{S}(\text{O})_n$ .
13. (Original) The inhibitor of claim 12, wherein  $\text{Y}^1$  is  $-(\text{CH}_2)\text{-S}(\text{O})_n\text{-(CH}_2)_p$ , where n is 0, 1, or 2, and p is 3, 4, or 5.
14. (Original) The inhibitor of claim 1, wherein W is  $-\text{C}(\text{O})\text{-NH-OM}$ , M being selected from the group consisting of hydrogen, sodium, potassium, magnesium, and calcium.
15. (Original) The inhibitor of claim 1, wherein W is  $-\text{C}(\text{O})\text{-NH-Z}$  or  $\text{NH-C}(\text{O})\text{-NH-Z}$ , Z being unsubstituted 2-anilinyll or unsubstituted 2-pyridyl.

16. (Original) The inhibitor of claim 1, wherein W is  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ ,  $\text{R}^2$  being selected from the group consisting of  $\text{C}_1-\text{C}_6$  alkyl,  $\text{C}_6-\text{C}_{10}$  aryl,  $(\text{C}_6-\text{C}_{10})\text{ar}(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6\text{alkyl})\text{Carbonyl}$ ,  $(\text{C}_6-\text{C}_{10}\text{aryl})\text{carbonyl}$ , and  $((\text{C}_6-\text{C}_{10})\text{ar}(\text{C}_1-\text{C}_6)\text{alkyl})\text{carbonyl}$ , wherein the aryl portion of any such groups may be optionally substituted.
17. (Original) The inhibitor of claim 16, wherein  $\text{R}^2$  is selected from the group consisting of methyl, phenyl, benzyl, benzoyl, and acetyl.
18. (Previously Amended) An inhibitor of histone deacetylase represented by formula (2):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

$\text{Y}^2$  is  $\text{C}_5-\text{C}_7$  alkylene, wherein said alkylene maybe optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting CY and W may be replaced with O,  $\text{NR}^3$ , or  $\text{S}(\text{O})_n$ , where  $\text{R}^3$  is hydrogen, alkyl, aryl, arakyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2, provided that  $\text{Y}^2$  is not an ester or amide linkage in the linear chain connecting Cy and W; and

W is selected from the group consisting of  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ ,  $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{Z}$ , and  $-\text{C}(\text{O})-\text{NH}-\text{Z}$ , where

$\text{R}^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted; and

Z is selected from the group consisting of aniliny, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, aniliny, methyl, or pyridymethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $\text{C}_1-\text{C}_4$  alkyl, or  $\text{C}_1-\text{C}_4$  alkoxy;

- provided that when W is  $-C(O)-CH_2-SR^2$ , the carbon atom in  $Y^2$  that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl.
19. (Original) The inhibitor of claim 18, wherein Cy is  $C_6-C_{10}$  aryl or is a radical of a heterocyclic moiety selected from the group consisting of thiophene, benzothiophene, furan, benzofuran, pyridine, uinoline, idole, isoquinoline, thiazole, morphonline, piperidine, piperazine, quinazolinone, benzotriazinone, phthalimide, and dioxobenzoisoquinoline, any of which groups may be optionally substituted.
20. (Original) The inhibitor of claim 18, wherein the aryl or heterocyclic moiety is substituted by one or two substituents independently selected from the group consisting of  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_6-C_{10}$  aryl, heteroaryl, heterocyclyl,  $(C_6-C_{10})ar(C_1-C_6)alkyl$ , halo, nitro, hydroxyl,  $C_1-C_6$  alkoxy,  $C_6-C_{10}$  aryloxy, heteroaryloxy,  $C_1-C_6$  alkoxycarbonyl,  $C_6-C_{10}$  aryloxycarbonyl, heteroaryloxycarbonyl, carboxy, and amino.
21. (Previously Amended) The inhibitor of claim 20, wherein Cy has the formula  $-Cy^1-Cy^2$  or  $Cy^1-G-Cy^2$ , wherein  $Cy^1$  and  $Cy^2$  are independently  $C_3-C_6$  cycloalkyl,  $C_6-C_{10}$  aryl, or a radical of a heterocyclic moiety, which groups optionally may be substituted, and G is O,  $NR^3$ , or  $S(O)_n$ , where  $R^3$  is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2.
22. (Cancelled)
23. (Original) The inhibitor of claim 18, wherein one to about four carbon atoms of the alkylene are independently substituted with halo, oxo, oximino, nitro, haloalkyl, alkyl, aralkyl, alkoxy, aryloxy, alkoxycarbonyl, carboxy, hydroxyalkyl, acyl, acyloxy, or cyano.
24. (Original) The inhibitor of claim 18, wherein one carbon atom in the linear chain connecting Cy and W is replaced with O,  $NR^3$ , or  $S(O)_n$ .

25. (Original) The inhibitor of claim 19, wherein one carbon atom in the linear chain connecting Cy and W is replaced with  $\text{NR}^3$ , where  $\text{R}^3$  is selected from the group consisting of  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_6\text{-C}_{10}$  aryl,  $(\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $(\text{C}_1\text{-C}_6\text{alkyl})\text{oxycarbonyl}$ ,  $(\text{C}_6\text{-C}_{10}\text{ aryl})\text{oxycarbonyl}$ ,  $((\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl})\text{oxycarbonyl}$ ,  $(\text{C}_1\text{-C}_6\text{ alkyl})\text{carbonyl}$ ,  $(\text{C}_6\text{-C}_{10}\text{ aryl})\text{carbonyl}$ , and  $((\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl})\text{carbonyl}$ .
26. (Original) The inhibitor of claim 18, wherein one or two carbon atoms in the linear chain connecting Cy and W are replaced by O.
27. (Original) The inhibitor of claim 18, wherein W is  $-\text{C}(\text{O})\text{-NH-Z}$  or  $-\text{NH-C}(\text{O})\text{-NH-Z}$ , Z being unsubstituted 2-aniliny1 or unsubstituted 2-pyridyl.
28. (Original) The inhibitor of claim 18, wherein W is  $-\text{C}(\text{O})\text{-CH}_2\text{-SR}^2$ ,  $\text{R}^2$  being selected from the group consisting of  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_6\text{-C}_{10}$  aryl,  $(\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $(\text{C}_1\text{-C}_6\text{ alkyl})\text{carbonyl}$ ,  $(\text{C}_6\text{-C}_{10}\text{ aryl})\text{carbonyl}$ , and  $((\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl})\text{carbonyl}$ , wherein the aryl portion of any such groups may be optionally substituted.
29. (Original) The inhibitor of claim 28, wherein  $\text{R}^2$  is selected from the group consisting of methyl, phenyl, benzyl, benzoyl, and acetyl.
30. (Currently amended) An inhibitor of histone deacetylase represented by formula (3):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted, provided that Cy is other than dimethylaminoaphthyl when  $\text{Y}^3$  is  $-(\text{CH}_2)_3-$ ;

$\text{Y}^3$  is  $\text{C}_2\text{-C}_6$  alkylene, wherein said alkylene may be optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxyl,

oxo, nitro, haloalkyl, alkyl, aralkyl, alkoxy, aryloxy, carboxy, hydroxyalkyl, acyl, acyloxy, and cyano; and

W is selected from the group consisting of  $-C(O)-CH_2-SR^2$ ,  $-C(O)-NH-OM$ ,  $-NH-C(O)-NH-Z$ , and  $-C(O)-NH-Z$ , where

$R^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen; or a pharmaceutically acceptable cation ~~and~~

Z is selected from the group consisting of aniliny, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinylmethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $C_1-C_4$  alkyl, or  $C_1-C_4$  alkoxy;

provided that Z does not have the formula  $-(C_5H_5N)-NHC(O)-Y^3-NH-S(O)_2-Cy$

or a pharmaceutically acceptable salt thereof.

31. (Original) The inhibitor of claim 30, wherein Cy is  $C_6-C_{10}$  aryl or is a radical of a heterocyclic moiety selected from the group consisting of thiophene, benzothiophene, furan, benzofuran, pyridine, quinoline, indole, isoquinoline, thiazole, morpholine, piperidine, and piperazine, any of which groups may be optionally substituted.
32. (Original) The inhibitor of claim 31, wherein the aryl or heterocyclic moiety is substituted by one or two substituents independently selected from the group consisting of  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_6-C_{10}$  aryl, heteroaryl, heterocyclyl,  $(C_6-C_{10})ar(C_1-C_6)alkyl$ , halo, nitro, hydroxyl,  $C_1-C_6$  alkoxy,  $C_6-C_{10}$  aryloxy, heteroaryloxy,  $C_1-C_6$  alkoxycarbonyl,  $C_6-C_{10}$  aryloxycarbonyl, heteroaryloxycarbonyl, carboxy, and amio.
33. (Previously Amended) The inhibitor of claim 30, wherein Cy has the formula  $-Cy^1-Cy^2$  or  $Cy^1-G-Cy^2$ , wherein  $Cy^1$  and  $Cy^2$  are independently  $C_3-C_6$  cycloalkyl,  $C_6-C_{10}$  aryl, or a radical of a heterocyclic moiety, which groups optionally may be substituted, and G is O,

$\text{NR}^3$ , or  $\text{S(O)}_n$ , where  $\text{R}^3$  is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and  $n$  is 0, 1, or 2.

34. (Cancelled)
35. (Original) The inhibitor of claim 30, wherein  $\text{Y}^3$  is a  $\text{C}_2\text{-C}_6$  alkylene optionally substituted with one or two non-hydrogen substituents independently selected from the group consisting of halo, hydroxyl, oxo, nitro,  $(\text{halo})_{1-5}(\text{C}_1\text{-C}_3)\text{alkyl}$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $(\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $\text{C}_1\text{-C}_6$  alkoxy,  $\text{C}_6\text{-C}_{10}$  arloxy, carboxy, hydroxy  $(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $\text{C}_1\text{-C}_6$  alkylcarbonyl,  $\text{C}_6\text{-C}_{10}$  arylcarbonyl,  $\text{C}_1\text{-C}_6$  alkylcarbonyloxy,  $\text{C}_6\text{-C}_{10}$  arylcarbonyloxy, and cyano.
36. (Original) The inhibitor of claim 33, wherein  $\text{Y}^3$  is an optionally substituted saturated  $\text{C}_4\text{-C}_5$  alkylene.
37. (Original) The inhibitor of claim 30, wherein  $\text{W}$  is  $-\text{C(O)-NH-OM}$ ,  $\text{M}$  being selected from the group consisting of hydrogen, sodium, potassium, magnesium, and calcium.
38. (Original) The inhibitor of claim 30, wherein  $\text{W}$  is  $-\text{C(O)-NH-Z}$  or  $-\text{NH-C(O)-NH-Z}$ ,  $\text{Z}$  being unsubstituted 2-anilinyl or unsubstituted 2-pyridyl.
39. (Original) The inhibitor of claim 30, where  $\text{W}$  is  $-\text{C(O)-CH}_2\text{-SR}^2$ ,  $\text{R}^2$  being selected from the group consisting of  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_6\text{-C}_{10}$  aryl,  $(\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $(\text{C}_1\text{-C}_6\text{alkyl})\text{carbonyl}$ ,  $(\text{C}_6\text{-C}_{10}\text{aryl})\text{carbonyl}$ , and  $((\text{C}_6\text{-C}_{10})\text{ar}(\text{C}_1\text{-C}_6)\text{alkyl})\text{carbonyl}$ , wherein the aryl portion of any such groups may be optionally substituted.
40. (Cancelled)
41. (Cancelled)
42. (Currently Amended) A pharmaceutical composition comprising an inhibitor of histone deacetylase represented by formula (1):





wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

X is selected from the group consisting of C=O, C=CH<sub>2</sub>, CH(OH), CH(OR<sup>1</sup>), C=N(OH), and C=N(OR<sup>1</sup>), where R<sup>1</sup> is alkyl, aryl, aralkyl, or acyl;

Y<sup>1</sup> is a C<sub>3</sub>-C<sub>7</sub> alkylene, wherein said alkylene may be optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting X and W may be replaced with O, NR<sup>3</sup>, or S(O)<sub>n</sub>, where R<sup>3</sup> is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2, provided that the atoms in Y<sup>1</sup> that are attached to X and to W are carbon atoms, and further provided that Y<sup>1</sup> does not comprise an ester or amide linkage in the linear chain connecting X and W; and

W is selected from the group consisting of -C(O)-CH<sub>2</sub>-SR<sup>2</sup>, -C(O)-NH-OM, -NH-C(O)-NH-Z, and -C(O)-NH-Z, where R<sup>2</sup> is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen or a pharmaceutically acceptable cation;

Z is selected from the group consisting of anilinyll, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinyllmethyl, or pyridymethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy; and

a pharmaceutically acceptable carrier, excipient, or diluent; provided that X is C=CH<sub>2</sub>, CH(OR<sup>1</sup>), C=N(OH), or C=N(OR<sup>1</sup>) when W is -C(O)-NH-OM and Cy is unsubstituted phenyl, dimethylaminophenyl, or methoxyphenyl; and

further provided that when W is  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ , the carbon atom in  $\text{Y}^1$  that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl;

~~or a pharmaceutically acceptable salt thereof.~~

43. (Currently Amended) A pharmaceutical composition comprising an inhibitor of histone deacetylase represented by formula (2):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

$\text{Y}^2$  is  $\text{C}_5\text{-C}_7$  alkylene, wherein said alkylene may be optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting Cy and W may be replaced with O,  $\text{NR}^3$ , or  $\text{S}(\text{O})_n$ , where  $\text{R}^3$  is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2, provided that  $\text{Y}^2$  ~~does not comprise~~ is not an ester or amide linkage in the linear chain connecting Cy and W; and

W is selected from the group consisting of  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ ,  $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{Z}$ , and  $-\text{C}(\text{O})-\text{NH}-\text{Z}$ , where  $\text{R}^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted; and

Z is selected from the group consisting of anilinyll, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinylmethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{C}_1\text{-C}_4$  alkoxy; and a pharmaceutically acceptable carrier, excipient, or diluent;

provided that when W is  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ , the carbon atom in  $\text{Y}^2$  that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl;

~~a pharmaceutically acceptable salt thereof.~~

44. (Original) A pharmaceutical composition comprising an inhibitor of histone deacetylase represented by formula (3):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted, provided that Cy is other than dimethylaminonaphthyl when  $\text{Y}^3$  is  $-(\text{CH}_2)_3-$ ;

$\text{Y}^3$  is  $\text{C}_2\text{-C}_6$  alkylene, wherein said alkylene may be optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxyl, oxo, nitro, haloalkyl, alkyl, aralkyl, alkoxy, aryloxy, carboxy, hydroxyalkyl, acyl, acyloxy, and cyano; and

W is selected from the group consisting of  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ ,  $-\text{C}(\text{O})-\text{NH-OM}$ ,  $-\text{NH-C}(\text{O})-\text{NH-Z}$ , and  $-\text{C}(\text{O})-\text{NH-Z}$ , where

$\text{R}^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen or a pharmaceutically acceptable cation; and

Z is selected from the group consisting of anilinyll, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinyllmehtyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{C}_1\text{-C}_4$  alkoxy; and

a pharmaceutically acceptable carrier, excipient, or diluent.

provided that Z does not have the formula  $-C_5H_3N)-NHC(O)-Y^3-NH-S(O)_2-Cy_{\frac{1}{2}}$

~~or a pharmaceutically acceptable salt thereof.~~

45. (Cancelled)
46. (Cancelled)
47. (Currently Amended) A method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with an inhibitor of histone deacetylase represented by formula (1):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

X is selected from the group consisting of C=O, C-CH<sub>2</sub>, CH(OH), CH(OR<sup>1</sup>), C=N(OH), and C=N(OR<sup>1</sup>), where R<sup>1</sup> is alkyl, aryl, aralkyl, or acyl;

Y<sup>1</sup> is a C<sub>3</sub>-C<sub>7</sub> alkylene, wherein said alkylene may be optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting X and W may be replaced with O, NR<sup>3</sup>, or S(O)<sub>n</sub>, where R<sup>3</sup> is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl, or carbamoyl, and n is 0, 1, or 2, provided that the atoms in Y<sup>1</sup> that are attached to X and W are carbon atoms, and further provided that Y<sup>1</sup> ~~does not comprise~~ is not an ester or amide linkage in the linear chain connecting X and W; and

W is selected from the group consisting of -C(O)-CH<sub>2</sub>-SR<sup>2</sup>-C(O)-NH-OM, -NH-C(O)-NH-Z, and -C(O)-NH-Z, where

$R^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen or a pharmaceutically acceptable cation;

Z is selected from the group consisting of aniliny, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinylmethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

provided that X is  $C=CH_2$ ,  $CH(OR^1)$ ,  $C=N(OH)$ , or  $C=N(OR^1)$  when W is  $-C(O)-NH-OM$  and Cy is unsubstituted phenyl dimethylaminophenyl, or methoxyphenyl; and

further provided that when W is  $-C(O)-CH_2-SR^2$ , the carbon atom in  $Y^1$  that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl;

~~or a pharmaceutically acceptable salt thereof.~~

48. (Previously Amended) A method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with an inhibitor of histone deacetylase represented by formula (2):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted;

$Y^2$  is  $C_5$ - $C_7$  alkylene, wherein said alkylene may be optionally substituted, and wherein one or two carbon atoms in the alkylene chain connecting Cy and W may be replaced with O,  $NR^3$ , or  $S(O)_n$ , where  $R^3$  is hydrogen, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl,

or carbamoyl, and  $n$  is 0, 1, or 2, provided that  $Y^2$  is not an ester or amide linkage in the linear chain connecting Cy and W; and

W is selected from the group consisting of  $-C(O)-CH_2SR^2$ ,  $-NH-C(O)-NH-Z$ , and  $-C(O)-NH-Z$ , where

$R^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted; and

Z is selected from the group consisting of anilinyll, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinemethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $C^1-C^4$  alkyl, or  $C_1-C_4$  alkoxy;

provided that when W is  $-C(O)-CH_2-SR^2$ , the carbon atom in  $Y^2$  that is attached to W is unsubstituted or is substituted with other than amino, acylamino, alkoxycarbonyl, or carbamoyl.

49. (Currently amended) A method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with an inhibitor of histone deacetylase represented by formula (3):



wherein

Cy is cycloalkyl, aryl, or a radical of a heterocyclic moiety, any of which may be optionally substituted, provided that Cy is other than dimethylaminonaphthyl when  $Y^3$  is  $-(CH_2)_3-$ ;

$Y^3$  is  $C_2-C_6$  alkylene, wherein said alkylene may be optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxyl, oxo, nitro, haloalkyl, alkyl, aralkyl, alkoxy, aryloxy, carboxy, hydroxyalkyl, acyl, acyloxy, and cyano; and

W is selected from the group consisting of  $-\text{C}(\text{O})-\text{CH}_2-\text{SR}^2$ ,  $-\text{C}(\text{O})-\text{NH}-\text{OM}$ ,  $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{Z}$ , and  $\text{C}(\text{O})-\text{NH}-\text{Z}$ , where

$\text{R}^2$  is alkyl, aryl, aralkyl, or acyl, wherein the aryl portion of any such groups may be optionally substituted;

M is hydrogen or a pharmaceutically acceptable cation; and

Z is selected from the group consisting of anilinyll, pyridyl, thiazolyl, hydroxyphenyl, thiadiazolyl, anilinyllmethyl, or pyridylmethyl, any of which groups optionally may be substituted with halo, hydroxyl, amino, nitro,  $\text{C}_1-\text{C}_4$  alkyl, or  $\text{C}-\text{C}_4$  alkoxy;

provided that Z does not have the formula  $-(\text{C}_5\text{H}_3\text{N})-\text{NHC}(\text{O})-\text{Y}^3-\text{NH}-\text{S}(\text{O})_2-\text{Cy}$ ;

~~or a pharmaceutically acceptable salt thereof.~~

Claims 50 - 56            (Cancelled)

57.    (New) The inhibitor according to claim 1, wherein the cation is a monovalent or divalent cation.
58.    (New) The inhibitor according to claim 30, wherein the cation is a monovalent or divalent cation.
59.    (New) The pharmaceutical composition according to claim 42, wherein the cation is a monovalent or divalent cation.
60.    (New) The pharmaceutical composition according to claim 44, wherein the cation is a monovalent or divalent cation.
61.    (New) The method according to claim 47, wherein the cation is a monovalent or divalent cation.

62. (New) The method according to claim 49, wherein the cation is a monovalent or divalent cation.